Clinical Science
Pathobiology of pulmonary hypertension: Impact on clinical management

https://doi.org/10.1053/tc.2000.6507Get rights and content

Abstract

Our previous studies showed how analysis of pulmonary vascular changes on lung biopsy tissue and on angiography added to the hemodynamic assessment of pulmonary vascular resistance in predicting the success of a surgical repair. Both the potential for heightened vasoreactivity in the early postoperative period and for reversibility of pulmonary vascular disease at later follow-up were correlated with qualitative and quantitative evaluation of arterial changes. The ability of continuous intravenous prostacylin to arrest progression and even induce regression of structurally advanced pulmonary vascular disease in some cases has led to rethinking how pathological material can be useful in clinical decision making. The presence of occlusive changes and particularly plexiform lesions was thought to represent irreversible disease, but the observation that ongoing cellular proliferation and connective tissue synthesis occurs even in advanced lesions thought to represent end stage ‘burnt-out’ lesions, led to re-evaluation of the potential of biologically reversing the disease process. Our laboratory has used clinical material, cultured cells, and studies in experimental animals to gain new insights into some of the mechanisms which lead to the progression of vascular changes, and has used this information in strategies aimed at arresting progression and, more recently, inducing regression of pulmonary hypertension and associated vascular lesions. Specifically, we have focused on the increased activity of an endogenous vascular elastase (EVE) and expression of the glycoproteins tenascin and fibronectin in the pathobiology of pulmonary hypertension. This report will first review our studies in children with congenital heart defects, assessment of reversibility of pulmonary hypertension, and then discuss more recent work addressing cellular and molecular mechanisms aimed at developing newer therapeutic strategies. Copyright © 2000 by W.B. Saunders Company

References (87)

  • N Boudreau et al.

    Fibronectin, hyaluronan and a hyaluronan binding protein contribute to increased ductus arteriosus smooth muscle cell migration

    Dev Biol

    (1991)
  • A Rendas et al.

    Aortopulmonary shunts in growing pigs

    J Thorac Cardiovasc Surg

    (1979)
  • J Schnader et al.

    Chronic pulmonary hypertension in sheep: Temporal progression of lesions

    J Surg Res

    (1996)
  • J Taipale et al.

    Human mast cell chymase and leukocyte elastase release latent transforming growth factor-β1 from the extracellular matrix of cultured human epithelial and endothelial cells

    J Biol Chem

    (1995)
  • S Meiners et al.

    Regulation of astrocytic tenascin by basic fibroblast growth factor

    Dev Biol

    (1993)
  • A Hinek et al.

    Functional interplay between interleukin-1 receptor and elastin binding protein regulates fibronectin production in coronary artery smooth muscle cells

    Exp Cell Res

    (1996)
  • M Rabinovitch et al.

    Lung biopsy in congenital heart disease: A morphometric approach to pulmonary vascular disease

    Circulation

    (1978)
  • B Meyrick et al.

    Ultrastructural findings in lung biopsy material from children with congenital heart defects

    Am J Pathol

    (1980)
  • M Rabinovitch et al.

    Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects

    Circulation

    (1984)
  • PR Hickey et al.

    Blunting of stressing responses of the pulmonary circulation of infants by fentanyl

    Anesth Analg

    (1985)
  • A Bush et al.

    Modification of pulmonary hypertension secondary to congenital heart disease with prostacyclin therapy

    Am Rev Resp Dis

    (1987)
  • C Houde et al.

    Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators

    Br Heart J

    (1993)
  • P Viles et al.

    The spectrum of pulmonary vascular disease in transposition of the great arteries

    Circulation

    (1969)
  • JD Waldman et al.

    Transposition of the great arteries with intact ventricular septum and patent ductus arteriosus

    Am J Cardiol

    (1977)
  • W Berman et al.

    The development of pulmonary vascular obstructive disease after successful Mustard operation in early infancy

    Circulation

    (1978)
  • M Rabinovitch et al.

    Quantitative analysis of the pulmonary wedge angiogram in congenital heart defects: Correlation with hemodynamic data and morphometric findings in lung biopsy tissue

    Circulation

    (1981)
  • E Juaneda et al.

    Pulmonary vascular structure in patients dying after a Fontan procedure: The lung as a risk factor

    Br Heart J

    (1984)
  • M Rabinovitch et al.

    Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: A correlation of light with scanning electron microscopy and transmission electron microscopy

    Lab Invest

    (1986)
  • M Rabinovitch et al.

    Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects

    Circulation

    (1987)
  • S Fuse et al.

    Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease

    Circulation

    (1994)
  • E Cutz et al.

    Pulmonary neuroendocrine cells in normal human lung and in pulmonary hypertension

    Lab Invest

    (1986)
  • KM Allen et al.

    A study of nerves containing peptides in the pulmonary vasculature of healthy infants and children and of those with pulmonary hypertension

    Br Heart J

    (1989)
  • C Youngson et al.

    Oxygen sensing in airway chemoreceptors

    Nature

    (1993)
  • MB Schindler et al.

    Increased respiratory system resistance in bronchial smooth muscle hypertrophy in children with acute postoperative pulmonary hypertension

    Am J Respir Crit Care Med

    (1995)
  • AT Dinh Xuan et al.

    Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger's syndrome

    Br J Pharmacol

    (1990)
  • I Adatia et al.

    Circulating endothelin levels in children with congenital heart disease

    Br Heart J

    (1993)
  • DS Celermajer et al.

    Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics

    Circulation

    (1993)
  • M Yoshibayashi et al.

    Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation

    Circulation

    (1991)
  • PL Jones et al.

    Induction of tenascin and fibronectin are features associated with increased smooth muscle cell proliferation during the development of progressive pulmonary hypertension in children

    Am J Pathol

    (1997)
  • PL Jones et al.

    Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the avβ3 integrin to promote epidermal growth factor receptor phosphorylation and growth

    J Cell Biol

    (1997)
  • PL Jones et al.

    Tenascin-C is induced with progressive pulmonary vascular disease in rats is functionally related to increased smooth muscle cell proliferation

    Circ Res

    (1996)
  • N Clausell et al.

    Upregulation of fibronectin synthesis by interleukin-1β in coronary artery smooth muscle cells is associated with the development of the post-cardiac transplant arteriopathy in piglets

    J Clin Invest

    (1992)
  • MD Botney et al.

    Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-β

    Am J Pathol

    (1994)
  • Cited by (0)

    Address reprint requests to Marlene Rabinovitch, MD, Director, Division of Cardiovascular Research, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1X8.

    View full text